This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
Dr Pomper joins Brecon from Nycomed Austria, where he was latterly associate director, global contract manufacturing. He brings extensive experience in pharmaceutical manufacturing and packing, having joined the industry in 1994 and worked for a number of national and multinational companies in the sector, including Fresenius Kabi, where he held senior positions covering disciplines including R&D, formulation development and documentation.
Based in Graz, Austria, Dr Pomper is briefed to manage and develop Brecon's relationships with its client base in the European pharma heartland, comprising Germany, France and Switzerland. He will also be responsible for burgeoning markets such as Spain, Portugal and Eastern Europe.
The appointment signals the intent of Brecon and its US parent company, AmerisourceBergen Corporation, to strengthen service levels for clinical drug development in continental Europe. Business development director Steve Kemp says, “Brecon's scope of service and reputation for excellence has earned us a loyal worldwide client base, encompassing countries as geographically and culturally diverse as the US and Japan.
“Closer to home, we see enormous potential as pharmaceutical producers in the countries that make up the European market, strive to bring new products to market while remaining competitive and compliant with the mass of legislation pertinent to the sector,” explains Kemp. “By partnering with Brecon, companies can concentrate on their core business of drug development and manufacture, secure in the knowledge that we will bring into play all our expertise in clinical supply, commercial packaging, storage & distribution, analytical and regulatory services. Setting up a base in mainland Europe will enable us to spread that message further and faster and we're delighted to have someone of Herbert's calibre on board.”
Dr Pomper is likewise confident that Brecon offers the perfect mix of expertise and resource for companies in the European market. “Specialisation is essential in the pharmaceutical sector and Brecon's focus ensures that it really understands the challenges its clients face and can help them overcome those challenges,” he says. “The company's global credentials are important too, as it is perfectly positioned to support clients with regional or worldwide product launches. The capability to provide a fast and flexible response, whatever the size of the job is a real asset and something that Brecon is well able to deliver, thanks to its combination of a highly skilled and motivated workforce and range of versatile production equipment.
“I predict a bright and exciting future for Brecon in Europe and am delighted to have the opportunity to play a role in its development,” concludes Dr Pomper.
Based in Graz, Austria, Dr Pomper is briefed to manage and develop Brecon's relationships with its client base in the European pharma heartland, comprising Germany, France and Switzerland. He will also be responsible for burgeoning markets such as Spain, Portugal and Eastern Europe.
The appointment signals the intent of Brecon and its US parent company, AmerisourceBergen Corporation, to strengthen service levels for clinical drug development in continental Europe. Business development director Steve Kemp says, “Brecon's scope of service and reputation for excellence has earned us a loyal worldwide client base, encompassing countries as geographically and culturally diverse as the US and Japan.
“Closer to home, we see enormous potential as pharmaceutical producers in the countries that make up the European market, strive to bring new products to market while remaining competitive and compliant with the mass of legislation pertinent to the sector,” explains Kemp. “By partnering with Brecon, companies can concentrate on their core business of drug development and manufacture, secure in the knowledge that we will bring into play all our expertise in clinical supply, commercial packaging, storage & distribution, analytical and regulatory services. Setting up a base in mainland Europe will enable us to spread that message further and faster and we're delighted to have someone of Herbert's calibre on board.”
Dr Pomper is likewise confident that Brecon offers the perfect mix of expertise and resource for companies in the European market. “Specialisation is essential in the pharmaceutical sector and Brecon's focus ensures that it really understands the challenges its clients face and can help them overcome those challenges,” he says. “The company's global credentials are important too, as it is perfectly positioned to support clients with regional or worldwide product launches. The capability to provide a fast and flexible response, whatever the size of the job is a real asset and something that Brecon is well able to deliver, thanks to its combination of a highly skilled and motivated workforce and range of versatile production equipment.
“I predict a bright and exciting future for Brecon in Europe and am delighted to have the opportunity to play a role in its development,” concludes Dr Pomper.
Companies in this article